Incyte Corporation - קפיטליזציית שוק INCY

Incyte Corporation (INCY) operates advanced biotech laboratories featuring automated screening to create innovative medicines. The company generates revenue in the global dermatology and oncology markets, utilizing profits from Jakafi to develop new projects, while its market capitalization stands at 23.48. This price chart on GURU.Markets clearly demonstrates the asset's dynamics. The business relies on monopoly positions in the therapy of rare hematological diseases, offering indispensable inhibitors.

The development of oncology drugs by Incyte Corporation (INCY) requires colossal investments and patent protection, which directly impacts the cost of equity. Multiplying the current share price by the number of outstanding shares quantifies the scale of the business, smoothing out speculative noise through the issuer's market valuation to analyze the long-term sustainability of the enterprise and the risks of sudden drawdowns.